WO2004078928A3 - T cell regulation - Google Patents
T cell regulation Download PDFInfo
- Publication number
- WO2004078928A3 WO2004078928A3 PCT/US2004/006133 US2004006133W WO2004078928A3 WO 2004078928 A3 WO2004078928 A3 WO 2004078928A3 US 2004006133 W US2004006133 W US 2004006133W WO 2004078928 A3 WO2004078928 A3 WO 2004078928A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- lag
- treg
- expression
- regulatory
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 5
- 230000009134 cell regulation Effects 0.000 title 1
- 102000017578 LAG3 Human genes 0.000 abstract 6
- 101150030213 Lag3 gene Proteins 0.000 abstract 5
- 230000000694 effects Effects 0.000 abstract 3
- 230000014509 gene expression Effects 0.000 abstract 3
- 238000000338 in vitro Methods 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 210000003289 regulatory T cell Anatomy 0.000 abstract 2
- 102000043131 MHC class II family Human genes 0.000 abstract 1
- 108091054438 MHC class II family Proteins 0.000 abstract 1
- 230000002223 anti-pathogen Effects 0.000 abstract 1
- 230000005809 anti-tumor immunity Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 238000003491 array Methods 0.000 abstract 1
- 230000005784 autoimmunity Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000010835 comparative analysis Methods 0.000 abstract 1
- 230000005014 ectopic expression Effects 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0381—Animal model for diseases of the hematopoietic system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Environmental Sciences (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
Abstract
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07021595.9A EP1897548B2 (en) | 2003-02-28 | 2004-03-01 | T cell regulation |
AU2004217526A AU2004217526B2 (en) | 2003-02-28 | 2004-03-01 | T cell regulation |
EP04716126A EP1596871A4 (en) | 2003-02-28 | 2004-03-01 | T cell regulation |
JP2006508934A JP2006523226A (en) | 2003-02-28 | 2004-03-01 | T cell regulation method |
CA2517287A CA2517287C (en) | 2003-02-28 | 2004-03-01 | Regulation of t cells by lag-3 (cd223) |
EP18177034.8A EP3427741A3 (en) | 2003-02-28 | 2004-03-01 | T cell regulation |
US10/547,371 US20060240024A1 (en) | 2003-02-28 | 2004-03-01 | T cell regulation |
US12/578,887 US8551481B2 (en) | 2003-02-28 | 2009-10-22 | Anti-cancer vaccine composition comprising an anti-CD223 antibody and kit comprising an anti-cancer vaccine and an anti-CD223 antibody |
US13/679,485 US9005629B2 (en) | 2003-02-28 | 2012-11-16 | Method for treating cancer with an antibody to CD223 protein |
US14/105,293 US20140127226A1 (en) | 2003-02-28 | 2013-12-13 | T Cell Regulation |
US14/973,806 US10787513B2 (en) | 2003-02-28 | 2015-12-18 | Methods for treatment comprising an antibody that binds CD223 protein |
US15/942,168 US10934354B2 (en) | 2003-02-28 | 2018-03-30 | Methods of increasing T cell immune response in the treatment of cancer |
US17/155,228 US20210230275A1 (en) | 2003-02-28 | 2021-01-22 | T cell regulation |
US18/206,552 US20240174747A1 (en) | 2003-02-28 | 2023-06-06 | T cell regulation |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45103903P | 2003-02-28 | 2003-02-28 | |
US60/451,039 | 2003-02-28 | ||
US48214303P | 2003-06-24 | 2003-06-24 | |
US60/482,143 | 2003-06-24 | ||
US53170403P | 2003-12-22 | 2003-12-22 | |
US60/531,704 | 2003-12-22 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10547371 A-371-Of-International | 2004-03-01 | ||
US10/547,371 A-371-Of-International US20060240024A1 (en) | 2003-02-28 | 2004-03-01 | T cell regulation |
US12/578,887 Continuation US8551481B2 (en) | 2003-02-28 | 2009-10-22 | Anti-cancer vaccine composition comprising an anti-CD223 antibody and kit comprising an anti-cancer vaccine and an anti-CD223 antibody |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004078928A2 WO2004078928A2 (en) | 2004-09-16 |
WO2004078928A3 true WO2004078928A3 (en) | 2005-06-23 |
Family
ID=32966451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/006133 WO2004078928A2 (en) | 2003-02-28 | 2004-03-01 | T cell regulation |
Country Status (13)
Country | Link |
---|---|
US (8) | US20060240024A1 (en) |
EP (4) | EP3427741A3 (en) |
JP (7) | JP2006523226A (en) |
AU (1) | AU2004217526B2 (en) |
CA (1) | CA2517287C (en) |
CY (1) | CY1114755T1 (en) |
DK (1) | DK1897548T4 (en) |
ES (1) | ES2439580T3 (en) |
HK (1) | HK1114339A1 (en) |
PL (1) | PL1897548T3 (en) |
PT (1) | PT1897548E (en) |
SI (1) | SI1897548T1 (en) |
WO (1) | WO2004078928A2 (en) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3427741A3 (en) | 2003-02-28 | 2019-02-13 | The Johns Hopkins University | T cell regulation |
WO2006044864A2 (en) * | 2004-10-19 | 2006-04-27 | Duke University | Vaccine adjuvant |
SI1928492T1 (en) * | 2005-09-01 | 2011-09-30 | Celgene Corp | Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy |
US20090317407A1 (en) * | 2006-05-02 | 2009-12-24 | Lacelle Michael G | Augmentation of immune response to cancer vaccine |
WO2008126940A1 (en) * | 2007-04-10 | 2008-10-23 | The University Of Tokyo | Novel t cell |
US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
EP1987839A1 (en) * | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
JP5616782B2 (en) * | 2008-03-14 | 2014-10-29 | 株式会社メディネット | Antibody with immune enhancement function |
EP2267118A4 (en) * | 2008-03-27 | 2013-08-28 | Takara Bio Inc | Method for production of transfected cell |
AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
US20120100160A1 (en) * | 2008-11-26 | 2012-04-26 | Immune Disease Institute | Methods for Inducing Mixed Chimerism |
DK2726101T3 (en) * | 2011-06-30 | 2018-12-03 | Genzyme Corp | T-CELL ACTIVATION INHIBITORS |
WO2013063504A1 (en) * | 2011-10-26 | 2013-05-02 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Platinum compounds that inhibit constitutive stat3 signaling and induce cell cycle arrest and apoptosis of malignant cells |
AR091649A1 (en) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
CA2936092A1 (en) | 2013-01-23 | 2014-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Stabilized hepatitis b core polypeptide |
TWI658051B (en) | 2013-03-15 | 2019-05-01 | 葛蘭素史密斯克藍智慧財產發展有限公司 | Antigen binding proteins |
EP2970909A4 (en) | 2013-03-15 | 2017-02-15 | The University of Chicago | Methods and compositions related to t-cell activity |
BR112016005816A2 (en) | 2013-09-20 | 2017-09-19 | Bristol Myers Squibb Co | COMBINATION OF ANTI-LAG-3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREAT TUMORS |
EP3757130A1 (en) * | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
US20170035864A1 (en) * | 2013-12-09 | 2017-02-09 | Bullet Biotechnology, Inc. | SPECIFIC VIRUS-LIKE PARTICLE-CpG OLIGONUCLEOTIDE VACCINES AND USES THEREOF |
JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
JOP20200096A1 (en) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | Antibody molecules to tim-3 and uses thereof |
WO2015125652A1 (en) * | 2014-02-21 | 2015-08-27 | Idacセラノスティクス株式会社 | Therapeutic agent for solid cancer |
MX2016011993A (en) | 2014-03-14 | 2016-12-09 | Novartis Ag | Antibody molecules to lag-3 and uses thereof. |
MX2016015614A (en) | 2014-05-28 | 2017-08-21 | Agenus Inc | Anti-gitr antibodies and methods of use thereof. |
TWI693232B (en) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof |
JO3663B1 (en) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | Anti-lag3 antibodies and antigen-binding fragments |
CN107206071A (en) | 2014-09-13 | 2017-09-26 | 诺华股份有限公司 | The conjoint therapy of ALK inhibitor |
EP4029508A1 (en) | 2014-10-10 | 2022-07-20 | Idera Pharmaceuticals, Inc. | Treatment of cancer using tlr9 agonists and checkpoint inhibitors |
EP3206711B1 (en) | 2014-10-14 | 2023-05-31 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
MA41463A (en) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | ANTIBODIES DIRECTED AGAINST LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) |
TWI702290B (en) * | 2015-04-07 | 2020-08-21 | 富禾生醫股份有限公司 | Modified natural killer t cells, pharmaceutical compositions and uses thereof |
EA039293B1 (en) * | 2015-06-05 | 2021-12-30 | Мерк Шарп И Доум Корп. | Anti-lag3 antibodies and antigen-binding fragments |
TWI773646B (en) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | Lag-3-binding molecules and methods of use thereof |
US11059880B2 (en) | 2015-06-30 | 2021-07-13 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Redirected cells with MHC chimeric receptors and methods of use in immunotherapy |
KR20180029238A (en) * | 2015-07-15 | 2018-03-20 | 피어이스 파마슈티컬즈 게엠베하 | A novel protein specific for LAG-3 |
PL3328419T3 (en) | 2015-07-30 | 2021-12-27 | Macrogenics, Inc. | Pd-1-binding molecules and methods of use thereof |
AU2016303497A1 (en) * | 2015-07-31 | 2018-03-01 | Tarveda Therapeutics, Inc. | Compositions and methods for immuno-oncology therapies |
CN117510633A (en) | 2015-09-02 | 2024-02-06 | 伊缪泰普有限公司 | anti-LAG-3 antibodies |
WO2017055404A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific antibodies specific for pd1 and tim3 |
TWI756187B (en) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | Anti-lag3 antibodies and uses thereof |
LT3376857T (en) | 2015-11-20 | 2021-06-25 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized lymphocyte-activation gene 3 |
EP3383430A4 (en) | 2015-12-02 | 2019-12-18 | Agenus Inc. | Antibodies and methods of use thereof |
MX2018007089A (en) | 2015-12-14 | 2019-01-30 | Macrogenics Inc | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof. |
WO2017106129A1 (en) | 2015-12-16 | 2017-06-22 | Merck Sharp & Dohme Corp. | Anti-lag3 antibodies and antigen-binding fragments |
US10947317B2 (en) | 2016-03-15 | 2021-03-16 | Mersana Therapeutics, Inc. | NaPi2b-targeted antibody-drug conjugates and methods of use thereof |
BR112018076281A2 (en) | 2016-06-20 | 2019-03-26 | Kymab Limited | immunocytocin, use of an immunocytocin, method, pharmaceutical composition, method for treating a proliferative disease in an animal, nucleic acid, vector, host and antibody or fragment thereof |
PL3476399T3 (en) * | 2016-06-23 | 2022-06-20 | Jiangsu Hengrui Medicine Co. Ltd. | Lag-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof |
RU2021127872A (en) | 2016-06-30 | 2021-11-09 | Онкорус, Инк. | DELIVERY OF THERAPEUTIC POLYPEPTIDES THROUGH PSEUDOTYPED ONCOLYTIC VIRUSES |
EA039718B1 (en) * | 2016-07-21 | 2022-03-03 | Регенерон Фармасьютикалз, Инк. | Anti-lag3 antibodies and uses thereof |
CA3036350A1 (en) * | 2016-09-08 | 2018-03-15 | Daiichi Sankyo Company, Limited | Anti-lag-3 antibody for treating autoimmune disease |
KR20230133934A (en) | 2016-10-11 | 2023-09-19 | 아게누스 인코포레이티드 | Anti-lag-3 antibodies and methods of use thereof |
WO2018086583A1 (en) * | 2016-11-11 | 2018-05-17 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric lag-3 |
CN108070613B (en) | 2016-11-11 | 2020-03-13 | 百奥赛图江苏基因生物技术有限公司 | Preparation method and application of humanized gene modified animal model |
US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
MX2019008434A (en) | 2017-01-18 | 2019-11-11 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding affinity for lag-3. |
CN118557758A (en) | 2017-02-10 | 2024-08-30 | 瑞泽恩制药公司 | Radiolabeled anti-LAG 3 antibodies for immune-PET imaging |
TW201834697A (en) | 2017-02-28 | 2018-10-01 | 美商梅爾莎納醫療公司 | Combination therapies of her2-targeted antibody-drug conjugates |
EP4201953A1 (en) | 2017-04-03 | 2023-06-28 | F. Hoffmann-La Roche AG | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
HUE060019T2 (en) | 2017-04-05 | 2023-01-28 | Hoffmann La Roche | Anti-lag3 antibodies |
CA3052532A1 (en) | 2017-04-05 | 2018-10-11 | F. Hoffmann-La Roche Ag | Bispecific antibodies specifically binding to pd1 and lag3 |
CN118356488A (en) | 2017-05-30 | 2024-07-19 | 百时美施贵宝公司 | Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody |
PL3631454T3 (en) | 2017-05-30 | 2024-01-29 | Bristol-Myers Squibb Company | Treatment of lag-3 positive tumors |
CA3067226A1 (en) * | 2017-06-16 | 2018-12-20 | Mayo Foundation For Medical Education And Research | Materials and methods for increasing immune responses |
JP6896989B2 (en) * | 2017-07-13 | 2021-06-30 | ナンジン リーズ バイオラブズ カンパニー リミテッド | Antibody-bound LAG-3 and its use |
US11638760B2 (en) | 2017-11-27 | 2023-05-02 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
US20220305127A1 (en) | 2017-12-21 | 2022-09-29 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
KR20200104314A (en) | 2017-12-22 | 2020-09-03 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | LAG-3 antibody pharmaceutical composition and use thereof |
US11865081B2 (en) | 2017-12-29 | 2024-01-09 | Virogin Biotech Canada Ltd. | Oncolytic viral delivery of therapeutic polypeptides |
CN111655730A (en) | 2018-01-31 | 2020-09-11 | 豪夫迈·罗氏有限公司 | Bispecific antibodies comprising an antigen binding site that binds to LAG3 |
MX2021004906A (en) | 2018-10-29 | 2021-09-10 | Mersana Therapeutics Inc | Cysteine engineered antibody-drug conjugates with peptide-containing linkers. |
CN111304247B (en) | 2018-12-20 | 2021-03-16 | 百奥赛图江苏基因生物技术有限公司 | Preparation method and application of humanized LAG-3 gene modified animal model |
CN109666699B (en) * | 2018-12-29 | 2023-02-28 | 杭州科兴生物科技有限公司 | LAG-3/MHC II blocking function and biological effect based drug rapid screening method |
US20220214333A1 (en) * | 2019-04-16 | 2022-07-07 | Regents Of The University Of Minnesota | Biomarker for transplantation tolerance induced by apoptotic donor leukocytes |
EA202192528A1 (en) | 2019-05-13 | 2022-01-27 | Регенерон Фармасьютикалз, Инк. | COMBINATION OF PD-1 INHIBITORS AND LAG-3 INHIBITORS TO IMPROVE EFFICIENCY IN CANCER TREATMENT |
CN111415707B (en) * | 2020-03-10 | 2023-04-25 | 四川大学 | Prediction method of clinical individuation tumor neoantigen |
CN111808192B (en) * | 2020-06-05 | 2022-02-15 | 北京天广实生物技术股份有限公司 | Antibodies that bind LAG3 and uses thereof |
JP2022176672A (en) * | 2021-05-17 | 2022-11-30 | 国立大学法人北海道大学 | Peptide and pharmaceutical composition |
WO2022245816A1 (en) * | 2021-05-18 | 2022-11-24 | Pelican Therapeutics, Inc. | Treatment of autoimmune inflammatory diseases with tnfrsf25-binding agents |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US3832253A (en) | 1973-03-21 | 1974-08-27 | Baxter Laboratories Inc | Method of making an inflatable balloon catheter |
US4667014A (en) | 1983-03-07 | 1987-05-19 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
CA1200416A (en) | 1983-05-13 | 1986-02-11 | Societe Des Produits Nestle S.A. | Food process |
US4658957A (en) * | 1985-01-28 | 1987-04-21 | Abbott Laboratories | Utility tray |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
FR2656800B1 (en) * | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | NEW PROTEINS PRODUCED BY HUMAN LYMPHOCYTES, DNA SEQUENCE ENCODING THESE PROTEINS AND PHARMACEUTICAL AND BIOLOGICAL APPLICATIONS. |
US5976877A (en) * | 1990-01-08 | 1999-11-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses |
JPH04167172A (en) | 1990-10-31 | 1992-06-15 | Nec Corp | Vector processor |
USRE38313E1 (en) | 1994-05-06 | 2003-11-11 | Institut Gustave Roussy | Soluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotype antibodies |
PT843557E (en) * | 1995-07-21 | 2003-03-31 | Applied Research Systems | METHODS FOR DETECTING ISOLAR INDENTIFYING AND LABELING AND SELECTING TH1 LYMPOCHOCYTES BY INTERMEDIATE LAG-3 PROTEIN |
WO1997032970A1 (en) | 1996-03-04 | 1997-09-12 | Targeted Genetics Corporation | Modified rapid expansion methods ('modified-rem') for in vitro propagation of t lymphocytes |
EP0904350B1 (en) * | 1996-03-04 | 2010-08-04 | Calyx Bio-Ventures Inc. | Modified rapid expansion methods ("modified-rem") for in vitro propagation of t lymphocytes |
WO1998023741A1 (en) * | 1996-11-28 | 1998-06-04 | Institut Gustave Roussy | Mutants of the lag-3 proteins, products for the expression of these mutants and use |
ATE271607T1 (en) * | 1996-11-29 | 2004-08-15 | Applied Research Systems | PREVENTING GRAVE RECOVERY IN TRANSPLANTS AND FOR PRODUCING UNIVERSAL GENE THERAPY HOST CELL, USING LYMPHOCYTE ACTIVATION GENE-3 (LAG-3) |
CN1196786C (en) * | 1996-11-29 | 2005-04-13 | 应用研究系统Ars股份公司 | Methods for preventing graft rejection in transplantation and for producing universal gene therapy host cell |
EP0900841A1 (en) * | 1997-06-18 | 1999-03-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | LAG-3 splice variants |
EP0893507A1 (en) * | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment |
JPH1164707A (en) * | 1997-08-13 | 1999-03-05 | Fuji Photo Optical Co Ltd | Zoom lens barrel |
US6432925B1 (en) * | 1998-04-16 | 2002-08-13 | John Wayne Cancer Institute | RNA cancer vaccine and methods for its use |
GB0007088D0 (en) * | 2000-03-23 | 2000-05-17 | Torsana A S | Detection of immunological memory determining the position of loci of pathologyand therapeutic t-cell conjugates |
IL158860A0 (en) | 2001-05-15 | 2004-05-12 | Agensys Inc | Nucleic acids and corresponding proteins entitled 101p3a11 or phor-1 useful in treatment and detection of cancer and pharmaceutical compositions containing the same |
EP1390385A4 (en) * | 2001-05-29 | 2004-11-24 | Sirna Therapeutics Inc | Nucleic acid based modulation of female reproductive diseases and conditions |
ATE394497T1 (en) * | 2001-06-12 | 2008-05-15 | Bayer Cropscience Ag | TRANSGENIC PLANTS THAT PRODUCE STARCH WITH HIGH AMYLOSE CONTENT |
PT2280070E (en) * | 2001-07-23 | 2015-10-29 | Univ Leland Stanford Junior | Methods and compositions for rnai mediated inhibition of gene expression in mammals |
EP3427741A3 (en) | 2003-02-28 | 2019-02-13 | The Johns Hopkins University | T cell regulation |
CA2530285C (en) | 2003-06-27 | 2019-12-24 | Abgenix, Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
AR069501A1 (en) * | 2007-11-30 | 2010-01-27 | Genentech Inc | ANTI-VEGF ANTIBODIES (VASCULAR ENDOTELIAL GROWTH FACTOR) |
-
2004
- 2004-03-01 EP EP18177034.8A patent/EP3427741A3/en active Pending
- 2004-03-01 PT PT70215959T patent/PT1897548E/en unknown
- 2004-03-01 WO PCT/US2004/006133 patent/WO2004078928A2/en active Application Filing
- 2004-03-01 SI SI200432110T patent/SI1897548T1/en unknown
- 2004-03-01 EP EP20130179162 patent/EP2659893A3/en not_active Withdrawn
- 2004-03-01 ES ES07021595T patent/ES2439580T3/en not_active Expired - Lifetime
- 2004-03-01 US US10/547,371 patent/US20060240024A1/en not_active Abandoned
- 2004-03-01 AU AU2004217526A patent/AU2004217526B2/en not_active Expired
- 2004-03-01 DK DK07021595.9T patent/DK1897548T4/en active
- 2004-03-01 JP JP2006508934A patent/JP2006523226A/en not_active Withdrawn
- 2004-03-01 PL PL07021595T patent/PL1897548T3/en unknown
- 2004-03-01 CA CA2517287A patent/CA2517287C/en not_active Expired - Lifetime
- 2004-03-01 EP EP07021595.9A patent/EP1897548B2/en not_active Expired - Lifetime
- 2004-03-01 EP EP04716126A patent/EP1596871A4/en not_active Withdrawn
-
2008
- 2008-09-08 HK HK08109961A patent/HK1114339A1/en not_active IP Right Cessation
-
2009
- 2009-10-22 US US12/578,887 patent/US8551481B2/en not_active Expired - Lifetime
-
2010
- 2010-11-12 JP JP2010253326A patent/JP2011116755A/en not_active Withdrawn
-
2012
- 2012-11-16 US US13/679,485 patent/US9005629B2/en not_active Expired - Lifetime
-
2013
- 2013-10-18 JP JP2013217056A patent/JP2014058523A/en not_active Withdrawn
- 2013-11-14 CY CY20131101011T patent/CY1114755T1/en unknown
- 2013-12-13 US US14/105,293 patent/US20140127226A1/en not_active Abandoned
-
2015
- 2015-12-18 US US14/973,806 patent/US10787513B2/en active Active
-
2016
- 2016-04-13 JP JP2016080113A patent/JP2016169216A/en not_active Withdrawn
-
2017
- 2017-07-24 JP JP2017142742A patent/JP6758259B2/en not_active Expired - Lifetime
-
2018
- 2018-03-30 US US15/942,168 patent/US10934354B2/en not_active Expired - Lifetime
-
2019
- 2019-04-05 JP JP2019072698A patent/JP2019135247A/en not_active Withdrawn
-
2021
- 2021-01-22 US US17/155,228 patent/US20210230275A1/en not_active Abandoned
- 2021-12-28 JP JP2021214040A patent/JP2022034067A/en active Pending
-
2023
- 2023-06-06 US US18/206,552 patent/US20240174747A1/en active Pending
Non-Patent Citations (3)
Title |
---|
SUBRAMANYAM M. ET AL: "Soluble human lymphocyte activation gene-3 modulates allospecific T cell responses", INT IMMUNOL, vol. 10, no. 4, 1998, pages 679 - 689, XP002291778 * |
WORKMAN C.J. ET AL: "Cutting edge: molecular analysis of the Negative Regulatory function of the Lymphocyte Activation Gene-3", J IMMUNOL, vol. 169, no. 10, 15 November 2002 (2002-11-15), pages 5392 - 5395, XP002376800 * |
WORKMAN C.J. ET AL: "Phenotypic analysis of the murine CD-4 related glycoprotein, CD223 (LAG-3)", EUR J IMMUNOL, vol. 32, no. 8, August 2002 (2002-08-01), pages 2255 - 2263, XP003000898 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004078928A3 (en) | T cell regulation | |
Pearl et al. | Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion | |
Litjens et al. | Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes | |
SG11201910143TA (en) | Combination of a cell therapy and an immunomodulatory compound | |
Hubbe et al. | Heat‐stable antigen/CD24 on mouse T lymphocytes: evidence for a costimulatory function | |
HK1086750A1 (en) | Pharmaceutical composition for inducing an immune response in a human or animal | |
Lucia et al. | Evidence of a selective depletion of a CD16+ CD56+ CD8+ natural killer cell subset during HIV infection | |
WO2005111083A3 (en) | Antibodies specific for glycoprotein vi and methods of producing these antibodies | |
WO2004013093A3 (en) | Cytotoxic agents containing novel potent taxanes and their therapeutic use | |
TW200612945A (en) | Aerosol suspension formulations containing TG 227 ea as propellant | |
EP0847452A4 (en) | Fluorescence resonance energy transfer screening assay for the identification of hiv-1 envelope glycoprotein-medicated cell | |
HUE038833T2 (en) | Generation of antigen specific T cells | |
EP1362788A3 (en) | Devices, systems and methods for the containing and use of liquid solutions | |
HK1033582A1 (en) | Antibodies to death receptor 4 (dr4) and uses thereof | |
WO2004050704A8 (en) | Therapeutic and diagnostic agents | |
Nakajima et al. | Inhibition of gamma delta T cell recognition by receptors for MHC class I molecules. | |
MXPA05009910A (en) | Controlled release system containing saccharose acetate isobutyrate. | |
AU2334301A (en) | Chemokine receptor binding heterocyclic compounds | |
BR9914957A (en) | Inhibition of cytotoxic t cells by selectin-p ligand antagonists (psgl) | |
AU2002223462A1 (en) | Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28 | |
Szelenyi et al. | Changes in the cholinergic system of lymphocytes due to mitogenic stimulation | |
WO2004007749A3 (en) | Methods and systems for extended in vitro culture of neuronal cells | |
Marx et al. | Additive effects of calcium antagonists on cyclosporin A-induced inhibition of T-cell proliferation | |
Ariga et al. | Instruction of naive CD4+ T‐cell fate to T‐bet expression and T helper 1 development: roles of T‐cell receptor‐mediated signals | |
WO2007031832A3 (en) | Use of bipyridine compound 'caerulomycin a' derivatives and analogs thereof as immunosuppressive agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2517287 Country of ref document: CA Ref document number: 2004716126 Country of ref document: EP Ref document number: 2004217526 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006508934 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2004217526 Country of ref document: AU Date of ref document: 20040301 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004217526 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004716126 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006240024 Country of ref document: US Ref document number: 10547371 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10547371 Country of ref document: US |